The Barclays Global Healthcare Conference seems to have
triggered a trend within insider trading in the medicine and
healthcare industries. Earlier we saw five insider buys the day
before Allscripts-Misys was set to present at the Barclays. Now
there are two directors from AngioDynamics (
) who invested nearly a million dollars back into their company
the very day they were set to present at the conference. Chairman
of the Board Vincent Bucci and Director Dennis Meteny bought
89,600 shares of AngioDynamics on Tuesday, March 12. Chairman
Bucci bought 85,000 shares at $10.77 per share for a total of
$915,450. Director Meteny bought 4,600 shares at $10.82 each for
a total amount of $49,772. Bucci and Meteny now hold 133,696 and
21,950 shares, respectively.
Vincent Bucci has been chairman of the board since July 2007.
Bucci has also been the President and CEO of Health Policy
Associates Inc., a consulting company, since 1992.
Director Dennis Meteny has been on the board of directors for
AngioDynamics since 2004. Meteny is currently the president and
CEO of Cygnus Manufacturing Company. He has a BS in accounting
from Pennsylvania State University and his MBA from the
University of Pittsburgh.
The Barclays Global Healthcare Conference has brought about
several noticeable insider buys within the medicine, medical
supplies and healthcare industries. Some of these other insider
buys come from Mela Sciences Inc. (
), Vision Sciences Inc. (
), Allscripts-Misys (
) and Opko Health (OPKO).
AngioDynamics is a company centralized in the medical services
and device industry with a market cap of $393.5 million. Based
out of Latham, N.Y., AngioDynamics was initially formed to
research and develop products used in interventional radiology.
The company now makes products that are used in a variety of
different medical fields. They produce and distribute diagnostic
catheters, vascular access products, angiographic products and
accessories, angioplasty products and renal therapy products.
ANGO is owned by the following Gurus: Chuck Royce (870,425
shares), Mario Gabelli (166,032 shares), Jim Simons (160,032
shares) and Steven Cohen (1,100 shares).
President and CEO Joseph DeVivo presented at the Barclays
yesterday afternoon about the business strategy and recent
corporate development within AngioDynamics. If you would like to
listen to the webcast of AngioDynamics' presentation at the
Barclays click here. The presentation will be available via
webcast for the next 90 days.
With its shares up 4.55%, AngioDynamics trades at $11.26.About
GuruFocus: GuruFocus.com tracks the stocks picks and portfolio
holdings of the world's best investors. This value investing site
offers stock screeners and valuation tools. And publishes daily
articles tracking the latest moves of the world's best investors.
GuruFocus also provides promising stock ideas in 3 monthly
newsletters sent to